Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KLS-0611
- Development stage
- Phase 2
- Lead developer
- Kissei Pharmaceutical
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
KLS-0611 is a small molecule P2Y2 receptor agonist being developed by Kissei Pharmaceutical for the treatment of dry eye syndrome. The P2Y2 receptor is a G protein-coupled receptor expressed on the ocular surface, including the conjunctival epithelium and goblet cells. Activation of this receptor by KLS-0611 triggers the release of mucin and electrolytes, which promotes the secretion of water and improves the quality and stability of the tear film. This mechanism is intended to alleviate the symptoms and signs of dry eye by restoring ocular surface homeostasis. The drug is currently in Phase 2 clinical testing in Japan.
02
Targets
JAK (Janus kinase family)
Beyond the preview
Go deeper on KLS-0611.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KLS-0611.